Today, it was all about oil afterOPEC “reached an understanding” on capping oil production. And that made Murphy Oil (MUR) the hottest stock in the S&P 500.
Murphy Oil soared 11% to$28.91 today, easily topping the S&P 500′s 0.5% rise to2,171.37.Front month Nymex Crude futures climbed $2.38 per barrel, or 5.3% to $47.05, while the Energy Select Sector SPDR ETF (XLE) jumped 4.3% to$69.78.
Murphy Oil, meanwhile, is one of those oil companies that’s particularly sensitive to changesin the price of oil. Oil goes up, Murphy gains. Oil goes down, Murphy drops. Simple. And boy did oil go up, thanks to OPEC.
Thanks to today’s 11% move, the stock now has a market capitalization of $4.5 billion. Not bad for a company that lost $2.3 billion on sales of $2.7 billion in 2015.
value investing: Aquinox Pharmaceuticals, Inc.(AQXP)
- [By Lee Jackson]
The Baker Brothers biotech hedge fund bought a block of 398,062 shares of Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) last week. At a per-shareprice of $17.18, the total for the trade came to$6,836,813.
value investing: Barclays PLC(BCS)
- [By Jon C. Ogg]
Barclays PLC (NYSE: BCS) was raised to Overweight from Equal Weight at Morgan Stanley. Its American depositary sharesclosed up 2.6% at $11.36 on Thursday and were indicated up 1.2% at $11.50 on Friday. The52-week range is $6.76 to $12.05.
- [By WWW.THESTREET.COM]
Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”
ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”
value investing: Chuy's Holdings, Inc.(CHUY)
- [By Peter Graham]
A long term performance chart shows Del Taco Restaurants now outperforming Mexican restaurant stock peers such as mid cap Chipotle Mexican Grill, Inc (NYSE: CMG) and small caps El Pollo LoCo Holdings Inc (NASDAQ: LOCO), Fiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY) have mostly been drifting lower lately:
- [By Peter Graham]
A long term performance chart shows El Pollo LoCo Holdings having fallen below its IPO price for retail investors, butsharesappear to have stabilized over the past year and a halfwhile potentialpeers like small capFiesta Restaurant Group Inc (NASDAQ: FRGI) and large cap Chipotle Mexican Grill, Inc (NYSE: CMG) have performed better in the past and small cap Chuy’s Holdings Inc (NASDAQ: CHUY) is moving sideways:
- [By Peter Graham]
A long term performance chart shows Chipotle Mexican Grills shares back to breakeven while of the small caps peers, El Pollo LoCo Holdings Inc (NASDAQ: LOCO) has had the worst performance, Fiesta Restaurant Group Inc (NASDAQ: FRGI) is off its 2015s peak and Chuy’s Holdings Inc (NASDAQ: CHUY) has been a mixed performer:
value investing: Federal-Mogul Holdings Corporation(FDML)
- [By Benzinga News Desk]
Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.
value investing: Coherus BioSciences, Inc.(CHRS)
- [By Lisa Levin]
Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.
- [By Lisa Levin] Gainers
Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Ben Levisohn]
Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:
Agence France-Presse/Getty Images
The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.